IMPE Abstracts

Background: Lonapegsomatropin (TransCon hGH) is a once-weekly prodrug of somatropin, approved for the treatment of pediatric growth hormone deficiency (pGHD) by the US FDA and EMA. In the pivotal phase 3 heiGHt trial, lonapegsomatropin demonstrated noninferior and superior annualized heigh velocity (AHV) and a comparable safety profile to daily somatropin in children with GHD. The ongoing open-label extension trial, enliGHten, enrolled participants from the he...

Background: Hysterosalpingography (HSG) using oil-soluble contrast medium (OSCM) improves fertility with pregnancy rates of approximately 40% reported in women within six months of the procedure. However, OSCM has high iodine content and long half-life resulting in severe and persistent maternal iodine excess for up to 6 months. Any fetus conceived during this time would be exposed to a high iodine load with the potential for thyroid dysfunction from the Wolff...